Jump to main content
Jump to site search

Issue 45, 2015
Previous Article Next Article

Graphene quantum dots for the inhibition of β amyloid aggregation

Author affiliations

Abstract

The aggregation of Aβ peptides is a crucial factor leading to Alzheimer's disease (AD). Inhibiting the Aβ peptide aggregation has become one of the most essential strategies to treat AD. In this work, efficient and low-cytotoxicity inhibitors, graphene quantum dots (GQDs) are reported for their application in inhibiting the aggregation of Aβ peptides. Compared to other carbon materials, the low cytotoxicity and great biocompatibility of GQDs give an advantage to the clinical research for AD. In addition, the GQDs may cross the blood–brain barrier (BBB) because of the small size. It is believed that GQDs may be therapeutic agents against AD. This work provides a novel insight into the development of Alzheimer's drugs.

Graphical abstract: Graphene quantum dots for the inhibition of β amyloid aggregation

Back to tab navigation

Supplementary files

Publication details

The article was received on 12 Sep 2015, accepted on 07 Oct 2015 and first published on 09 Oct 2015


Article type: Paper
DOI: 10.1039/C5NR06282A
Author version
available:
Download author version (PDF)
Citation: Nanoscale, 2015,7, 19060-19065
  •   Request permissions

    Graphene quantum dots for the inhibition of β amyloid aggregation

    Y. Liu, L. Xu, W. Dai, H. Dong, Y. Wen and X. Zhang, Nanoscale, 2015, 7, 19060
    DOI: 10.1039/C5NR06282A

Search articles by author

Spotlight

Advertisements